TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 946338

Group type: EXPERIMENTAL
Intervention: Pimozide (2 mg initially, then 1 mg/day)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Fusaric acid (600 mg/day)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Pimozide and Fusaric acid
Number of subjects: 8
Study: 29956374

Group type: EXPERIMENTAL
Intervention: Public perception of river fish biodiversity
Number of subjects: 4000

Group type: EXPERIMENTAL
Intervention: Support for conservation measures
Number of subjects: 4000

Group type: EXPERIMENTAL
Intervention: Perception of threats to biodiversity
Number of subjects: 4000

Group type: EXPERIMENTAL
Intervention: Conservation messaging effectiveness
Number of subjects: 4000
Study: 30169244

Group type: EXPERIMENTAL
Intervention: Sildenafil 25 mg three times daily until 32 weeks and 0 days' gestation or delivery
Number of subjects: 135

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Sildenafil
Number of subjects: 135
Study: 27829464

Group type: EXPERIMENTAL
Intervention: Minimally Invasive Ponto Surgery (MIPS) technique
Number of subjects: 62

Group type: COMPARATOR
Intervention: Linear incision technique with soft tissue preservation
Number of subjects: 62
Study: 24513094

Group type: EXPERIMENTAL
Intervention: Topical treatment with timolol 0.5%
Number of subjects: 127

Group type: COMPARATOR
Intervention: Topical treatment with brimonidine 0.2%
Number of subjects: 127
Study: 22452789

Group type: EXPERIMENTAL
Intervention: Hypertonic saline infusion after a 4-day high sodium diet (300 mmol sodium/day)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Hypertonic saline infusion after a 4-day low sodium diet (30 mmol sodium/day)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Baseline measurements
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Hypertonic saline infusion during high sodium intake
Number of subjects: 41

Group type: COMPARATOR
Intervention: Baseline and post-saline measurements of u-PGE2, u-cAMP, AVP, PRC, Ang II, Aldo, ANP, and BNP
Number of subjects: 41
Study: 19281321

Group type: EXPERIMENTAL
Intervention: Circular muscle exercises (Paula method)
Number of subjects: 245

Group type: COMPARATOR
Intervention: Pelvic floor muscle training (PFMT)
Number of subjects: 245
Study: 17189794

Group type: EXPERIMENTAL
Intervention: Gatifloxacin eyedrops (4 subgroups)
Number of subjects: 193

Group type: EXPERIMENTAL
Intervention: Moxifloxacin eyedrops (4 subgroups)
Number of subjects: 193

Group type: EXPERIMENTAL
Intervention: Moxifloxacin (wick method)
Number of subjects: 193

Group type: COMPARATOR
Intervention: Gatifloxacin and Moxifloxacin (comparison)
Number of subjects: 193
Study: 16080835

Group type: EXPERIMENTAL
Intervention: Bisoprolol (10 mg qd)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Carvedilol (25 mg bid)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Conventional therapy (control group)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Beta-blocker therapy (both bisoprolol and carvedilol)
Number of subjects: 44
Study: 12228887

Group type: EXPERIMENTAL
Intervention: New weighted goodness-of-fit tests
Number of subjects: 0

Group type: COMPARATOR
Intervention: Hosmer-Lemeshow decile-of-risk test
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pearson chi-square test
Number of subjects: 0

Group type: COMPARATOR
Intervention: Unweighted sum-of-squares tests
Number of subjects: 0
Study: 10426128

Group type: EXPERIMENTAL
Intervention: lonidamine (450 mg daily p.o. until progression)
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: vindesine (3 mg/m2/daily i.v. weekly for 4 weeks and then every 2 weeks until progression)
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: lonidamine + vindesine (at the same dose and schedule)
Number of subjects: 126

Group type: COMPARATOR
Intervention: supportive therapy only
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: lonidamine
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: vindesine
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: lonidamine + vindesine
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: lonidamine or vindesine
Number of subjects: 126
Study: 7493300

Group type: EXPERIMENTAL
Intervention: Recombinant interferon-alpha 2a (IFN-alpha 2a) starting dose 6 MU, adjusted based on ALT response
Number of subjects: 67

Group type: COMPARATOR
Intervention: No therapy (control)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Recombinant interferon-alpha 2a (IFN-alpha 2a)
Number of subjects: 67
Study: 2178643

Group type: EXPERIMENTAL
Intervention: Simulation group with endotracheal tube introducer
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group with standard intubation techniques
Number of subjects: 40
Study: 499287

Group type: EXPERIMENTAL
Intervention: Cyproheptadine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Metergoline
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31753866

Group type: EXPERIMENTAL
Intervention: Supervised exercise training (3 weekly sessions of 35 min moderate intensity walking/running and 25 min resistance training until delivery)
Number of subjects: 91
Study: 27759898

Group type: EXPERIMENTAL
Intervention: Adenosine 12 mg
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Adenosine 18 mg
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Adenosine 24 mg
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Adenosine (all doses)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Adenosine (doses 18 mg and 24 mg)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Adenosine (in patients >110 kg)
Number of subjects: 50
Study: 26423650

Group type: EXPERIMENTAL
Intervention: BMS-663068 400 mg twice daily
Number of subjects: 254

Group type: EXPERIMENTAL
Intervention: BMS-663068 800 mg twice daily
Number of subjects: 254

Group type: EXPERIMENTAL
Intervention: BMS-663068 600 mg once daily
Number of subjects: 254

Group type: EXPERIMENTAL
Intervention: BMS-663068 1200 mg once daily
Number of subjects: 254

Group type: COMPARATOR
Intervention: Ritonavir-boosted atazanavir
Number of subjects: 254

Group type: EXPERIMENTAL
Intervention: BMS-663068 groups
Number of subjects: 254
Study: 23507186

Group type: EXPERIMENTAL
Intervention: Duloxetine (60 mg/day)
Number of subjects: 30
Study: 21123763

Group type: EXPERIMENTAL
Intervention: Normobaric hypoxia (NH)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Sham
Number of subjects: 23
Study: 19418213

Group type: EXPERIMENTAL
Intervention: CHRM2 genetic variation (marker rs8191992 and additional SNPs)
Number of subjects: 4350

Group type: EXPERIMENTAL
Intervention: Additional 29 SNPs in CHRM2 (Australian sample) and 7 SNPs in English cohort
Number of subjects: 4350
Study: 17413836

Group type: EXPERIMENTAL
Intervention: Honey dressing
Number of subjects: 36

Group type: COMPARATOR
Intervention: Ethoxy‐diaminoacridine plus nitrofurazone dressing
Number of subjects: 36
Study: 15126548

Group type: EXPERIMENTAL
Intervention: 0.9 mg recombinant human TSH (rhTSH)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Isotonic saline (control)
Number of subjects: 9
Study: 11431171

Group type: EXPERIMENTAL
Intervention: t.i.d. tiagabine (three times daily)
Number of subjects: 347

Group type: COMPARATOR
Intervention: b.i.d. tiagabine (twice daily)
Number of subjects: 347

Group type: EXPERIMENTAL
Intervention: t.i.d. tiagabine
Number of subjects: 347

Group type: COMPARATOR
Intervention: b.i.d. tiagabine
Number of subjects: 347
Study: 9701179

Group type: EXPERIMENTAL
Intervention: TFA-free canola oil blend
Number of subjects: 38

Group type: COMPARATOR
Intervention: TFA-containing canola oil blend
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: TFA-free polyunsaturated oil blend
Number of subjects: 38

Group type: COMPARATOR
Intervention: TFA-containing polyunsaturated oil blend
Number of subjects: 38

Group type: COMPARATOR
Intervention: Butter
Number of subjects: 38
Study: 1572037

Group type: COMPARATOR
Intervention: Placebo for 4 weeks
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Transient ST segment depression
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Left ventricular hypertrophy
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Transient ST segment abnormalities during daily activities
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Repetitive VA
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: 3-year follow-up
Number of subjects: 150
Study: 2860135

Group type: EXPERIMENTAL
Intervention: Alprazolam
Number of subjects: 1

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1
Study: 29272068

Group type: EXPERIMENTAL
Intervention: Camelina Sativa Oil (10 g d‐1 ALA)
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Fatty Fish (four fish meals/week)
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Lean Fish (four fish meals/week)
Number of subjects: 79

Group type: COMPARATOR
Intervention: Control (limited intakes of fish and sources of ALA)
Number of subjects: 79
Study: 26780945

Group type: EXPERIMENTAL
Intervention: onabotulinumtoxinA (Botox)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: abobotulinumtoxinA (Dysport)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: incobotulinumtoxinA (Xeomin)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: All neurotoxin groups
Number of subjects: 57
Study: 25118597

Group type: EXPERIMENTAL
Intervention: Pre-transplant sclerostin levels
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Post-transplant sclerostin levels
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Pre-transplant sclerostin levels and time after transplantation
Number of subjects: 42
Study: 23554756

Group type: EXPERIMENTAL
Intervention: Rehabilitation training for 3 months starting 3 days after percutaneous coronary intervention
Number of subjects: 57

Group type: COMPARATOR
Intervention: Control group (no rehabilitation training)
Number of subjects: 57
Study: 19410716

Group type: EXPERIMENTAL
Intervention: Chemotherapy plus cetuximab
Number of subjects: 1125

Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 1125
Study: 17064957

Group type: EXPERIMENTAL
Intervention: peg-IFNalpha-2a (180mg/week) plus RBV (800mg/day) for 24 weeks
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: peg-IFNalpha-2a (180mg/week) plus RBV (800mg/day) for 24 weeks (n=35)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: peg-IFNalpha-2a plus RBV
Number of subjects: 41
Study: 15127083

Group type: EXPERIMENTAL
Intervention: 1.25 mg lorazepam
Number of subjects: 12

Group type: COMPARATOR
Intervention: 100 mg caffeine
Number of subjects: 12

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 12
Study: 12462516

Group type: EXPERIMENTAL
Intervention: Attentional shifts directed by central visual symbolic cues with SOA of 300 ms, 700 ms, or 1,100 ms
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Attentional shifts directed by central visual symbolic cues
Number of subjects: 0
Study: 15512028

Group type: EXPERIMENTAL
Intervention: Calcium supplementation
Number of subjects: 510

Group type: EXPERIMENTAL
Intervention: Low-dose aspirin
Number of subjects: 510

Group type: EXPERIMENTAL
Intervention: Combination of calcium and low-dose aspirin
Number of subjects: 510

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 510
Study: 8830066

Group type: EXPERIMENTAL
Intervention: Moclobemide
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 2195514

Group type: EXPERIMENTAL
Intervention: Piezoelectric inhalation device
Number of subjects: 0

Group type: COMPARATOR
Intervention: Metered-dose aerosols
Number of subjects: 0
Study: 761518

Group type: EXPERIMENTAL
Intervention: Step-ladder exercise
Number of subjects: 79

Group type: COMPARATOR
Intervention: Bicycle ergometry
Number of subjects: 79
Study: 31571135

Group type: EXPERIMENTAL
Intervention: Bright light therapy (BLT)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo therapy
Number of subjects: 16
Study: 28629318

Group type: EXPERIMENTAL
Intervention: 0.05% chlorhexidine oral rinse solution
Number of subjects: 103

Group type: COMPARATOR
Intervention: Usual oral hygiene care (Control)
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Functional Oral Intake Scale (FOIS)-level
Number of subjects: 103
Study: 25329436

Group type: EXPERIMENTAL
Intervention: Integrated family planning services into HIV care
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control sites (non-integrated FP services)
Number of subjects: 30
Study: 23867539

Group type: EXPERIMENTAL
Intervention: 0.9% NaCl
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: HES
Number of subjects: 56
Study: 21487057

Group type: EXPERIMENTAL
Intervention: Betamethasone 12 mg intramuscularly for two consecutive days
Number of subjects: 320

Group type: COMPARATOR
Intervention: Placebo intramuscularly for two consecutive days
Number of subjects: 320
Study: 19435472

Group type: EXPERIMENTAL
Intervention: Intensive insulin therapy
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 100
Study: 16687939

Group type: EXPERIMENTAL
Intervention: History of hypertension
Number of subjects: 15414
Study: 15491494

Group type: EXPERIMENTAL
Intervention: Psychologically based behavioural change programme delivered by telephone
Number of subjects: 365

Group type: EXPERIMENTAL
Intervention: Psychologically based behavioural change programme delivered face-to-face in the family home
Number of subjects: 365

Group type: COMPARATOR
Intervention: Brief written advice (comparison group)
Number of subjects: 365

Group type: EXPERIMENTAL
Intervention: Self-report of individual and family activity, psychological mediators of behaviour change, physiological and biochemical correlates, acceptability, and costs
Number of subjects: 365
Study: 11387277

Group type: COMPARATOR
Intervention: 100 IU recombinant FSH
Number of subjects: 179

Group type: EXPERIMENTAL
Intervention: 200 IU recombinant FSH
Number of subjects: 179
Study: 9219211

Group type: EXPERIMENTAL
Intervention: hands on clip-on aero-handlebars (AP)
Number of subjects: 14
Study: 8050140

Group type: EXPERIMENTAL
Intervention: Dietary supplementation with a combination of n‐3 (marine oil) and n‐6 (evening primrose oil) essential fatty acids
Number of subjects: 37

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 37
Study: 2903876

Group type: EXPERIMENTAL
Intervention: Doxepin (25 mg)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Desipramine (25 mg)
Number of subjects: 33
Study: 31042283

Group type: COMPARATOR
Intervention: Artery-first procedure
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Vein-first procedure
Number of subjects: 86
Study: 28371687

Group type: EXPERIMENTAL
Intervention: Cumulative incidence of T2DM
Number of subjects: 1137

Group type: EXPERIMENTAL
Intervention: Cumulative incidence of prediabetes
Number of subjects: 1137

Group type: EXPERIMENTAL
Intervention: Risk factors for T2DM
Number of subjects: 1137

Group type: EXPERIMENTAL
Intervention: Risk factors for prediabetes
Number of subjects: 1137
Study: 26728914

Group type: EXPERIMENTAL
Intervention: Medical female students
Number of subjects: 480

Group type: COMPARATOR
Intervention: Non-medical female students
Number of subjects: 480

Group type: EXPERIMENTAL
Intervention: Smoker students
Number of subjects: 480
Study: 23321547

Group type: EXPERIMENTAL
Intervention: Pazopanib 800 mg daily
Number of subjects: 435

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 435

Group type: EXPERIMENTAL
Intervention: Pazopanib (post-hoc analysis)
Number of subjects: 435

Group type: EXPERIMENTAL
Intervention: Pazopanib (RPSFT analysis)
Number of subjects: 435
Study: 21596247

Group type: EXPERIMENTAL
Intervention: Hydrophobic Acrysof IOL
Number of subjects: 68

Group type: COMPARATOR
Intervention: Hydrophilic C‐flex IOL (hydrophilic group C)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Hydrophilic Akreos Adapt IOL (hydrophilic group A)
Number of subjects: 68
Study: 19627681

Group type: EXPERIMENTAL
Intervention: Physiotherapy intervention including manual therapy, exercises, and psychological strategies, tailored individually with a maximum of six treatments over an 8-week period.
Number of subjects: 300
Study: 17122240

Group type: EXPERIMENTAL
Intervention: Stimulating catheters
Number of subjects: 41

Group type: COMPARATOR
Intervention: Nonstimulating catheters
Number of subjects: 41
Study: 14720242

Group type: EXPERIMENTAL
Intervention: True acupoint acupressure
Number of subjects: 44

Group type: COMPARATOR
Intervention: Sham acupressure
Number of subjects: 44
Study: 11399822

Group type: EXPERIMENTAL
Intervention: WBC-reduced RBCs
Number of subjects: 520

Group type: COMPARATOR
Intervention: Non-WBC-reduced RBCs
Number of subjects: 520
Study: 9005881

Group type: EXPERIMENTAL
Intervention: Aldrich formulas for predicting final QRS MI size
Number of subjects: 529

Group type: EXPERIMENTAL
Intervention: New formulas using ST-segment deviation, Q wave, and T wave information
Number of subjects: 529
Study: 8119472

Group type: EXPERIMENTAL
Intervention: Bologna procedure (B)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Ingelman-Sundberg procedure (IS)
Number of subjects: 100
Study: 3518072

Group type: EXPERIMENTAL
Intervention: dezocine 10 mg
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: dezocine 15 mg
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: butorphanol 2 mg
Number of subjects: 157

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 157
Study: 28639229

Group type: EXPERIMENTAL
Intervention: MHAA4549A (400, 1200, or 3600 mg)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Oseltamivir (75 mg twice daily from days 7 to 11)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: MHAA4549A
Number of subjects: 60
Study: 27632919

Group type: EXPERIMENTAL
Intervention: Prescription omega-3 acid ethyl esters (O3AEE) 1 g/d
Number of subjects: 461

Group type: COMPARATOR
Intervention: Olive oil placebo
Number of subjects: 461
Study: 24254537

Group type: EXPERIMENTAL
Intervention: Pulmonary vein isolation (PVI)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Left atrial maze (LAM)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Control (PVI)
Number of subjects: 52
Study: 22349588

Group type: EXPERIMENTAL
Intervention: Specific exercise strategy (strengthening eccentric exercises for the rotator cuff and concentric/eccentric exercises for the scapula stabilisers)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Specific exercise strategy
Number of subjects: 102

Group type: COMPARATOR
Intervention: Control exercise programme (unspecific movement exercises for the neck and shoulder)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Control exercise programme
Number of subjects: 102
Study: 21524017

Group type: EXPERIMENTAL
Intervention: Concept mapping teaching
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traditional lectures (Control)
Number of subjects: 0
Study: 18194489

Group type: COMPARATOR
Intervention: Intravenous glucose tolerance test (IVGTT)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Oral glucose tolerance test (OGTT)
Number of subjects: 108
Study: 17323547

Group type: EXPERIMENTAL
Intervention: Parenteral intake of 10% glucose solution with minerals (Group B)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Special drink consisting of sugars (mainly maltodextrin) mixed with minerals (Group C)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Starvation from midnight (Group A)
Number of subjects: 0
Study: 12673731

Group type: EXPERIMENTAL
Intervention: Cisplatin, vincristine, and fluorouracil (n = 20 patients)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Cisplatin and continuous-infusion doxorubicin (n = 26 patients)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Overall cohort
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: FL-HCC vs typical HCC
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Advanced-stage disease
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Response to treatment
Number of subjects: 46
Study: 10922234

Group type: EXPERIMENTAL
Intervention: sTNFR1 and sTNFR2 levels in ELF samples from allergic subjects during midseason in high-pollen-count period
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: sTNFR1 and sTNFR2 levels in ELF samples from allergic subjects during midseason in low-pollen-count period
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: sTNFR1 and sTNFR2 levels in ELF samples from allergic subjects in high-pollen-count period
Number of subjects: 22

Group type: COMPARATOR
Intervention: sTNFR1 and sTNFR2 levels in ELF samples from healthy subjects
Number of subjects: 22
Study: 8679045

Group type: EXPERIMENTAL
Intervention: Total Intravenous Anaesthesia (TIVA) with antiemetic prophylaxis (2.5 mg DHBP)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Total Intravenous Anaesthesia (TIVA) without antiemetic prophylaxis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Balanced Anaesthesia with antiemetic prophylaxis (2.5 mg DHBP)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Balanced Anaesthesia without antiemetic prophylaxis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Total Intravenous Anaesthesia (TIVA) with DHBP
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Balanced Anaesthesia with DHBP
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Total rate of postoperative complications (intraocular bleedings)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intraocular pressure in TIVA groups
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intraocular pressure in balanced anaesthesia groups
Number of subjects: 0
Study: 1506791

Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study: 6369557

Group type: EXPERIMENTAL
Intervention: mebendazole 500 mg thrice daily for 21 days
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: mebendazole 500 mg thrice daily + levamisole hydrochloride 2.5 mg/kg weekly for 3 weeks
Number of subjects: 0
Study: 31591650

Group type: EXPERIMENTAL
Intervention: 14 mg/d lactolycopene for 12 weeks
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo for 12 weeks
Number of subjects: 60
Study: 31562797

Group type: EXPERIMENTAL
Intervention: Nivolumab plus ipilimumab (1 mg/kg and 3 mg/kg respectively every 3 weeks for four doses, followed by nivolumab 3 mg/kg every 2 weeks)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nivolumab (3 mg/kg every 2 weeks) plus ipilimumab-matched placebo
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ipilimumab (3 mg/kg every 3 weeks for four doses) plus nivolumab-matched placebo
Number of subjects: 0
Study: 27362401

Group type: EXPERIMENTAL
Intervention: Local allergen extracts
Number of subjects: 0

Group type: COMPARATOR
Intervention: Imported allergen extracts
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Skin prick test (SPT) results
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Specific IgE (sIgE) levels
Number of subjects: 0